Company profile: VectivBio
1.1 - Company Overview
Company description
- Provider of clinical-stage biotechnology solutions developing transformational medicines for serious rare diseases. Offerings include LINZESS (linaclotide) for IBS-C and CIC; apraglutide, an investigational once-weekly GLP-2 analog for SBS-IF; CNP-104, a potential treatment for primary biliary cholangitis; and IW-3300, a GC-C agonist in development for visceral pain conditions including IC/BPS and endometriosis.
Products and services
- Apraglutide: VectivBio develops an investigational, once-weekly GLP-2 analog for Short Bowel Syndrome with intestinal failure (SBS-IF), evaluated as a potential treatment for affected patients
- CNP-104: VectivBio architects a clinical-stage potential treatment for primary biliary cholangitis (PBC), a rare autoimmune disease targeting the liver
- IW-3300: VectivBio develops a development-stage GC-C agonist for the potential treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome (IC/BPS) and endometriosis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to VectivBio
C2 Therapeutics
HQ: United States
Website
- Description: Provider of ablation therapies to treat diseases of the gastrointestinal tract.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full C2 Therapeutics company profile →
Sequana Medical
HQ: Switzerland
Website
- Description: Provider of implantable pump systems to manage fluid balance by moving excess fluid to the bladder for natural elimination. Products include the Alfapump, a fully implanted device that automatically pumps fluid from the abdominal cavity into the bladder, and DSR (Direct Sodium Removal), a therapy to manage fluid overload in heart failure by controlling sodium levels.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sequana Medical company profile →
Spirus Medical
HQ: United States
Website
- Description: Provider of advanced care medical devices for the gastrointestinal and cardiovascular markets, offering a product portfolio that includes the Endo-Ease Discovery and Dexterity Steerable Introducer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Spirus Medical company profile →
Napo Pharmaceuticals
HQ: United States
Website
- Description: Provider of proprietary pharmaceuticals for gastrointestinal indications and insulin-resistant diseases, offering Mytesi (crofelemer) for chronic diarrhea in HIV/AIDS on antiretroviral therapy; NP-300, a drug candidate for moderate to severe infectious diarrhea including cholera; NP-500 for insulin-resistant diseases; CRO-IBS for diarrhea-predominant IBS; and an Investigator-Initiated Trials program on crofelemer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Napo Pharmaceuticals company profile →
Ironwood Pharmaceuticals
HQ: United States
Website
- Description: Provider of pharmaceuticals for gastrointestinal and cardiovascular diseases, including LINZESS (linaclotide) for IBS-C and CIC; and a pipeline of investigational therapies: apraglutide for SBS-IF; CNP-104 for primary biliary cholangitis; and IW-3300, a GC-C agonist for visceral pain conditions such as interstitial cystitis/bladder pain syndrome and endometriosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Ironwood Pharmaceuticals company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for VectivBio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to VectivBio
2.2 - Growth funds investing in similar companies to VectivBio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for VectivBio
4.2 - Public trading comparable groups for VectivBio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →